WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/179424    International Application No.:    PCT/US2014/036102
Publication Date: 06.11.2014 International Filing Date: 30.04.2014
A61K 31/739 (2006.01), C40B 40/14 (2006.01), G01N 33/53 (2006.01), G01N 33/574 (2006.01), G01N 33/576 (2006.01), G01N 33/68 (2006.01)
Applicants: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD [GB/GB]; University Offices, Wellington Square Oxford OX1 2JD (GB).
UNITHER VIROLOGY, LLC [US/US]; 1733 Connecticut Avenue, NW Washington, District of Columbia 20009-1108 (US)
Inventors: LAING, Peter; (GB).
DWEK, Raymond; (GB).
POLLOCK, Stephanie; (GB).
ZITZMANN, Nicole; (GB)
Agent: MAEBIUS, Stephen B.; Foley & Lardner LLP 3000 K Street, NW Suite 600 Washington, District of Columbia 20007 (US)
Priority Data:
61/818,621 02.05.2013 US
Abstract: front page image
(EN)Lipidomic markers for Hepatitis C and related conditions, treat hepatic fibrosis and hepatocellular carcinoma. An agent administered to such subject may be an iminosugar, which may be effective against hepatitis C. Such iminosugar may be, for example, one of N- substituted deoxynojrimycins and pharmaceutically acceptable salts thereof, N-substituted deoxygalactonojirimycins and pharmaceutically acceptable salts thereof and N-substituted Me- deoxygalactonojirimycins and pharmaceutically acceptable salts thereof. A method of assessing a Hepatitis C infection or a condition caused by or associated with said infection. This method comprises: obtaining a biological sample from a subject in need thereof; determining a level of at least one Hepatitis C lipidomic biomarker in said biological sample; and comparing said level of with a control level of said Hepatitis C lipidomic biomarker to assess the Hepatitis C infection or the condition caused by or associated with said infection in the subject.
(FR)La présente invention concerne de nouveaux marqueurs lipidomiques pour l'hépatite C et des états associés, tels la fibrose hépatique et un carcinome hépatocellulaire.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)